कंपनी का अवलोकन
Mangoceuticals, Inc. operates within the United States healthcare sector, specifically focusing on health information services by developing, marketing, and selling men's wellness products and services through a specialized telemedicine platform. The company's product portfolio includes erectile dysfunction solutions under the Mango brand, hair loss treatments under the Grow brand, and hormone balance formulations, all delivered via digital medical consultation channels. This enterprise maintains a significantly small operational scale, employing only three individuals while managing a market capitalization of $5.77 million and generating annual revenues of $456,021. The valuation metrics indicate that despite its niche focus on digital health and men's wellness, the company carries a market cap that is disproportionately large relative to its current revenue stream, suggesting a high valuation multiple typical of early-stage biotech or healthcare technology firms that prioritize future growth potential over current profitability.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $456,021, yet it recorded a substantial net loss of $-21,818,994 and an EBITDA of $-15,869,579, revealing a severe disconnect where operating expenses drastically exceed revenue generation. The gross margin stands at 54.9%, indicating that the company retains a healthy portion of revenue after direct costs of goods sold, while the operating margin plunges to -1576.4% and the profit margin sits at 0.0%, highlighting an extremely aggressive burn rate where administrative and research costs consume nearly all income. Despite the significant net loss, the firm maintains a positive free cash flow of $1.88 million and holds a cash balance of $1.49 million, which provides a degree of financial flexibility to fund operations without immediate external financing. However, the balance sheet shows a debt obligation of $307,823 against a debt-to-equity ratio of 2.02, indicating a leveraged position where liabilities significantly outweigh equity. The current ratio of 1.74 suggests adequate short-term liquidity to cover obligations, though the massive negative net income relative to cash reserves warrants caution regarding long-term sustainability. Furthermore, the return on equity is -141.7% and the return on assets is -69.9%, metrics that collectively demonstrate that management has not yet generated positive returns on shareholder capital or asset deployment, reflecting the high-risk nature of the current business model.
मूल्यांकन आकलन
Mangoceuticals, Inc. reports a P/E ratio (TTM) of N/A and a forward P/E of N/A, a status that arises from the absence of positive net income and prevents standard earnings-based valuation comparisons. The price-to-book ratio is recorded at 0.30, implying that the market values the company's equity at significantly less than its book value, a common characteristic for unprofitable firms where assets are often undervalued on the balance sheet. The price-to-sales ratio stands at 12.65, and the EV/EBITDA is -0.29, suggesting that investors are pricing the stock based on revenue growth expectations rather than current profitability, while the negative EV/EBITDA reinforces the lack of earnings power in the current period. The stock has traded between a 52-week high of $2.88 and a 52-week low of $0.16, illustrating a massive price range where the current market price sits near the lower end of the historical trading band relative to the high. The beta value of 2.55 indicates that the stock exhibits high volatility, moving with more intensity than the broader market, which introduces substantial risk for holders seeking stable returns.
Growth & Income
The company experienced a year-over-year revenue decline of -10.3%, while earnings growth is marked as N/A due to persistent losses, indicating that the business is contracting rather than expanding in terms of top-line performance. Since the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute cash to shareholders but instead retains its limited cash reserves to fund ongoing development and operational costs. This reinvestment strategy is typical for pre-revenue or loss-making healthcare companies attempting to achieve profitability in a competitive men's wellness market. The overall growth and income profile is characterized by negative revenue momentum, zero dividend income, and a reliance on cash burn to sustain operations, presenting a high-risk investment scenario with no current income generation for equity holders.